Cooley, Paul Hastings Steer Gene Therapy Firm's $100M IPO
Gene-therapy focused biotechnology firm Lexeo Therapeutics Inc. has priced a $100 million initial public offering, represented by Cooley LLP and underwriters counsel Paul Hastings LLP....To view the full article, register now.
Already a subscriber? Click here to view full article